Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.47 |
| ▸ | WNT3A | P56704 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 6/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276797 | 0.91 | LTC4S (0.49) | CTNNB1WNT3AMAPTPLK1PLK3 | |
| SCHEMBL2272399 | 0.84 | ACLY (0.59) | CTNNB1WNT3ANAMPTMAPTIDO1 | |
| SCHEMBL4217800 | 0.82 | MEN1 (0.49) | CTNNB1WNT3AMAPTIDO1 | |
| SCHEMBL2271421 | 0.81 | DHODH (0.63) | MAPTPLK1PLK3DHODH | |
| SCHEMBL2275929 | 0.81 | KMT2A (0.62) | MAPTCA12CA1CA4CA7 | |
| SCHEMBL2269797 | 0.80 | SERPINE1 (0.50) | NAMPTDHODH | |
| SCHEMBL2272111 | 0.79 | SUCNR1 (0.59) | MAPTDHODH | |
| SCHEMBL2277740 | 0.79 | CYP1A2 (0.58) | — | |
| SCHEMBL2270925 | 0.79 | PLK1 (0.57) | MAPTCA12CA1CA4CA7 | |
| SCHEMBL2270906 | 0.78 | MEN1 (0.56) | MAPTLMNACA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | CTNNB1 1347/4885WNT3A 667/4885NAMPT 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.